Checkmate CMP-001-010

A multicenter, open-label, phase 2 study of intratumoral CMP-001 in combination withintravenous nivolumab in subjects with refractory unresectable or metastatic melanoma

Trial overview

Topic

Checkmate CMP-001-010

Description

This is a multicenter, open-label, Phase 2 clinical study of CMP-001 administered by IT injection in combination with intravenous (IV) nivolumab in subjects with unresectable or metastatic melanoma refractory to prior programmed cell death protein 1 (PD-1) blockade

Physicians

Contact

Florida East Coast-Jacksonville

Maddie Hamilton